-
公开(公告)号：US20120309007A1
公开(公告)日：2012-12-06
申请号：US13571124
申请日：2012-08-09
IPC分类号： G01N21/64 , G01N33/574 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57434 , G01N2333/96455
摘要： Described herein are method, compositions and kits for prognosis of prostate cancer. The methods comprise: determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The present invention features a method for prognosing prostate cancer in a sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
摘要翻译： 本文描述了前列腺癌预后的方法，组合物和试剂盒。 方法包括：确定PCA3和尿液样品中前列腺特异性标记物表达的比例，并将PCA3 /前列腺特异性标志物比值与患者前列腺癌的侵袭性和死亡风险相关联。 本发明的特征在于在患者样品中预测前列腺癌的方法，包括：评估前列腺癌特异性PCA3 mRNA的量和样品中前列腺特异性标志物的量; 确定该量前列腺癌特异性PCA3 mRNA的比值超过前列腺特异性标记量; 将所述比值与至少一个预定临界值进行比较，其中高于所述预定临界值的比率值指示与低于所述预定临界值的比率值相比较，前列腺癌死亡风险更高。
-
2.发明申请mRNA Ratios in Urinary Sediments and/or Urine as a Prognostic and/or Theranostic Marker for Prostate Cancer 有权尿沉渣和/或尿液中的mRNA比例作为前列腺癌的预后和/或前列腺标志物公开(公告)号：US20100021884A1
公开(公告)日：2010-01-28
申请号：US11794048
申请日：2005-12-23
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57434 , G01N2333/96455
摘要： Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and PSA expression in a urine sample and (b) correlating the value of the PCA3/PSA ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of PSA in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of PSA; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
摘要翻译： 本文描述了受试者中前列腺癌预后的方法和试剂盒。 方法包括：（a）确定尿液样品中PCA3和PSA表达的比例，以及（b）将PCA3 / PSA比值与患者前列腺癌的侵袭性和死亡风险相关联。 还描述了用于预测前列腺癌的试剂盒。 更具体地，本发明的特征在于一种用于在患者的生物样品中预测前列腺癌的方法，包括：评估前列腺癌特异性PCA3 mRNA的量和生物样品中的PSA量; 确定该量的前列腺癌特异性PCA3 mRNA与PSA量的比值; 将所述比值与至少一个预定临界值进行比较，其中高于所述预定临界值的比率值指示与低于所述预定临界值的比率值相比较，前列腺癌死亡风险更高。
-
3.发明申请mRNA RATIOS IN URINARY SEDIMENTS AND/OR URINE AS A PROGNOSTIC AND/OR THERANOSTIC MARKER FOR PROSTATE CANCER 有权尿酸酶和/或尿液中的mRNA比例作为前列腺癌的预防和/或治疗标记公开(公告)号：US20120003640A1
公开(公告)日：2012-01-05
申请号：US13101440
申请日：2011-05-05
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57434 , G01N2333/96455
摘要： Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and (b) correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
摘要翻译： 本文描述了受试者中前列腺癌预后的方法和试剂盒。 方法包括：（a）确定尿样中PCA3和前列腺特异性标记物表达的比例，以及（b）将PCA3 /前列腺特异性标志物比值与前列腺癌的侵袭性和死亡风险相关联 主题。 还描述了用于预测前列腺癌的试剂盒。 更具体地，本发明的特征在于在患者的生物样品中预测前列腺癌的方法，包括：评估前列腺癌特异性PCA3 mRNA的量和生物样品中前列腺特异性标志物的量; 确定该量前列腺癌特异性PCA3 mRNA的比值超过前列腺特异性标记量; 将所述比值与至少一个预定临界值进行比较，其中高于所述预定临界值的比率值指示与低于所述预定临界值的比率值相比较，前列腺癌死亡风险更高。
-
4.发明授权mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer 有权尿沉渣和/或尿液中的mRNA比值作为前列腺癌的预后和/或前列腺标志物公开(公告)号：US08257924B2
公开(公告)日：2012-09-04
申请号：US13101440
申请日：2011-05-05
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57434 , G01N2333/96455
摘要： Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and (b) correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
摘要翻译： 本文描述了受试者中前列腺癌预后的方法和试剂盒。 方法包括：（a）确定尿样中PCA3和前列腺特异性标记物表达的比例，以及（b）将PCA3 /前列腺特异性标志物比值与前列腺癌的侵袭性和死亡风险相关联 主题。 还描述了用于预测前列腺癌的试剂盒。 更具体地，本发明的特征在于在患者的生物样品中预测前列腺癌的方法，包括：评估前列腺癌特异性PCA3 mRNA的量和生物样品中前列腺特异性标志物的量; 确定该量前列腺癌特异性PCA3 mRNA的比值超过前列腺特异性标记量; 将所述比值与至少一个预定临界值进行比较，其中高于所述预定临界值的比率值指示与低于所述预定临界值的比率值相比较，前列腺癌死亡风险更高。
-
5.发明授权mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer 有权尿沉渣和/或尿液中的mRNA比值作为前列腺癌的预后和/或前列腺标志物公开(公告)号：US07960109B2
公开(公告)日：2011-06-14
申请号：US11794048
申请日：2005-12-23
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57434 , G01N2333/96455
摘要： Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and PSA expression in a urine sample and (b) correlating the value of the PCA3/PSA ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of PSA in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of PSA; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
摘要翻译： 本文描述了受试者中前列腺癌预后的方法和试剂盒。 方法包括：（a）确定尿液样品中PCA3和PSA表达的比例，以及（b）将PCA3 / PSA比值与患者前列腺癌的侵袭性和死亡风险相关联。 还描述了用于预测前列腺癌的试剂盒。 更具体地，本发明的特征在于一种用于在患者的生物样品中预测前列腺癌的方法，包括：评估前列腺癌特异性PCA3 mRNA的量和生物样品中的PSA量; 确定该量的前列腺癌特异性PCA3 mRNA与PSA量的比值; 将所述比值与至少一个预定临界值进行比较，其中高于所述预定临界值的比率值指示与低于所述预定临界值的比率值相比较，前列腺癌死亡风险更高。
-
-
-
-
搜索结果
5 条记录 (耗时 0.029 秒)
